Cerebrospinal fluid (CSF) total tau protein (τT) is increased in Alzheimer’s disease (AD) and may be of some help in the diagnostic work-up of demented patients. The aim of the present study was to investigate the diagnostic aid and the additional help (over that of clinical criteria) of τT in different clinical situations. Double-sandwich enzyme-linked immunosorbent assay was used to quantify τT in 61 healthy controls and 241 patients with various neuropsychiatric diseases. Our results suggest that CSF τT offers significant additional information over that of clinical criteria of AD, for the discrimination of AD from normal aging, depression, synucleinopathy, and possibly vascular dementia. However, for the differential diagnosis from frontotemporal dementia, corticobasal ganglionic degeneration, and secondary dementia, the diagnostic value is inadequate.
Sobów T, Flirski M, Liberski PP. Amyloid-beta and tau proteins as biochemical markers of Alzheimer’s disease. Acta Neurobiol Exp. 2004;64:53-70.
3.
Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch Neurol. 1994;51:888-895.
4.
Klatka LA, Schiffer RB, Powers JM, Kazee AM. Incorrect diagnosis of Alzheimer’s disease: a clinicopathologic study. Arch Neurol. 1996;53:35-42.
5.
MacKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939-944.
6.
Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of probable Alzheimer’s disease over the last two decades: I. Neurology. 2000;55:1854-1862.
7.
Risse SC, Raskind MA, Nochlin D, et al. Neuropathological findings in patients with clinical diagnoses of probable Alzheimer’s disease. Am J Psychiatry. 1990;147:168-171.
8.
Gilleard CJ, Kellett JM, Coles JA, et al. The St George’s dementia bed investigation study. Acta Psychiatr Scand. 1992;85:264-269.
Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDSAIREN International Workshop. Neurology. 1993;43:250-260.
11.
Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
12.
Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology. 1996;47:1-9.
13.
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113-1124.
14.
Larsen JP, Dupont E.Tandberg E.Clinical diagnosis of Parkinson’s disease: proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand. 1994;89:242-251.
15.
Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163:94-98.
16.
Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis: subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘Clinical limits of amyotrophic lateral sclerosis’ workshop contributors. J Neurol Sci. 1994;124(suppl):96-107.
17.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed.Washington, DC: American Psychiatric Association; 1994.
18.
Folstein M, Folstein S, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
19.
Fountoulakis KN, Tsolaki M, Chantzi H, Kazis A.Mini-Mental State Examination (MMSE): a validation study in Greece. Am J Alzheimer’s Dis. 2000;15:342-346.
20.
Morris JC. Classification of dementia and Alzheimer’s disease. Acta Neurol Scand. 1996;93(suppl 165):41-50.
21.
Tsolaki M, Foundoulakis C, Pavlopoulos I, et al. Prevalence and incidence of Alzheimer’s disease and other dementing disorders in Pylea, Greece. Am J Alzheimer’s Dis. 1999;14:138-148.
22.
Wallin A, Blennow K.Clinical subgroups of the Alzheimer’s syndrome. Acta Neurol Scand. 1996;93(suppl 165):51-57.
23.
Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993;61:1828-1834.
24.
Blennow K, Wallin A, Agren H, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer’s disease?Mol Chem Neuropathol. 1995;26:231-245.
25.
Shoji M, Matsubara E, Murakami T, et al. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol Aging. 2002;23:363-370.
26.
Nagga K, Gottfries J, Blennow K, Marcusson J.Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord. 2002;14:183-190.
27.
Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau as a biochemical marker for Alzheimer’s disease: a community based follow up study. J Neurol Neurosurg Psychiatry. 1998;64:298-305.
28.
Schönknecht P, Pantel J, Hunt A, et al. Levels of total tau and tau protein phosphorylated at threonin 181 in patients with incipient and manifest Alzheimer’s disease. Neurosci Lett. 2003;339:172-174.
29.
Kurz A, Riemenschneider M, Buch K, et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest stage of Alzheimer’s disease. Alzheimer Dis Assoc Disord. 1998;12:372-377.
30.
Shoji M, Matsubara E, Kanai M, et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer’s disease. J Neurol Sci. 1998;158:134-140.
31.
Andreasen N, Minthon L, Clarberg A, et al. Sensitivity, specificity and stability of CSF-tau in a community-based patient sample. Neurology. 1999;53:1488-1494.
32.
Gomez-Tortosa E, Gonzalo I, Fanjul S, et al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol. 2003;60:1218-1222.
33.
Kanemaru K, Kameda N, Yamanouchi H.Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology. 2000;54:1875-1876.
34.
Molina JA, Benito-León J, Jiménez-Jiménez FJ, et al. Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson’s disease patients. Neurosci Lett. 1997;238:139-141.
35.
Mitani K, Furiya Y, Uchihara T, et al. Increased CSF tau protein in corticobasal degeneration. J Neurol. 1998;245:44-46.
36.
Urakami K, Mori M, Wada K, et al. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci Lett. 1999;259:127-129.
37.
Süssmuth SD, Reiber H, Tumani H.Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett. 2001;300:95-98.
38.
Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer’s disease. Neurology. 1995;45:788-793.
39.
Hutton M, Lendon CL, Rizzu P, et al. Association of missence and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702-705.
40.
Spillantini MG, Goedert M.Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998;21:428-433.
41.
Arai H, Morikawa Y, Higuchi M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun. 1997;236:262-264.
42.
Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer’s disease. Neurosci Lett. 1999;259:133-135.
43.
Mecocci P, Cherubini A, Bregbocchi M, et al. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer’s disease?Alzheimer Dis Assoc Disord. 1998;12:211-214.
44.
Sjögren M, Rosengren L, Minthon L, et al. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 2000;54:1960-1964.
45.
Tato RE, Frank A, Hernanz A.Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 1995;59:280-283.
46.
Mori H, Hosoda K, Matsubara E, et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett. 1995;186:181-183.
47.
Leszek J, Malyszczak K, Janicka B, et al. Total tau in cerebrospinal fluid differentiates Alzheimer’s disease from vascular dementia. Med Sci Monit. 2003;9:CR484-CR488.
48.
Tarvonen-Schröoder S, Räihä I, Kurki T, et al. Clinical characteristics of rapidly progressive leuko-araiosis. Acta Neurol Scand. 1995;91:399-404.
49.
Holmes SE, O’Hearn EE, McInnis MG, et al. Expansion of a novel CAG trinucleotide repeat in the 5-prime region of PPP2R2B is associated with SCA12. Nature Genet. 1999;23:391-392.
50.
Sontag E, Nunbhakdi-Craig V, Lee G, et al. Molecular interactions among protein phosphatase 2A, tau, and microtubules. J Biol Chem. 1999;274:25490-25498.
51.
Cairns NJ, Atkinson PF, Hanger DP, et al. Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer’s disease. Neurosci Lett. 1997;230:49-52.
52.
Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297:187-190.
53.
Kapaki E, Kilidireas K.Paraskevas GP, Michalopoulou M, Patsouris E.Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer’s disease?J Neurol Neurosurg Psychiatry. 2001;71:401-403.
54.
Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998;19:109-116.
55.
Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58:373-379.
56.
Hampel H, Teipel SJ, Padberg F, et al. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukine-6 receptor complex in the diagnosis of Alzheimer’s disease. Brain Res. 1999;823:104-112.
57.
Kapaki E, Paraskevas GP, Zalonis I, Zournas C.CSF tau protein and beta-amyloid (1-42) in Alzheimer’s disease diagnosis: discrimination from normal aging and other dementias in the Greek population. Eur J Neurol. 2003;10:119-128.
58.
Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, et al. Biochemical diagnosis of Alzheimer’s disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol. 2003;60:1202-1206.
